CYP17 gene polymorphism in relation to breast cancer risk: a case-control study
- PMID: 16280037
- PMCID: PMC1410739
- DOI: 10.1186/bcr1319
CYP17 gene polymorphism in relation to breast cancer risk: a case-control study
Abstract
Introduction: The c.1-34T>C 5' promoter region polymorphism in cytochrome P450c17 (CYP17), a key enzyme in the biosynthesis of estrogen, has been associated with breast cancer risk, but most previous studies have been relatively small.
Methods: We genotyped 1,544 incident cases of primary breast cancer and 1,502 population controls, all postmenopausal Swedish women, for the CYP17 c.1-34T>C polymorphism and calculated odds ratios (ORs) and 95% confidence intervals (CIs) from logistic regression models.
Results: No overall association was found between CYP17 c.1-34T>C and breast cancer risk, OR 1.0 (95% CI 0.8-1.3) for the A2/A2 (CC) carriers compared to the A1/A1 (TT) carriers, regardless of histopathology. We detected an interaction between CYP17 c.1-34T>C and age at menarche (P = 0.026) but regarded that as a chance finding as no dose-response pattern was evident. Other breast cancer risk factors, including menopausal hormone use and diabetes mellitus, did not modify the overall results.
Conclusion: It is unlikely that CYP17 c.1-34T>C has a role in breast cancer etiology, overall or in combination with established non-genetic breast cancer risk factors.
Similar articles
-
CYP17 genetic polymorphism, breast cancer, and breast cancer risk factors: Australian Breast Cancer Family Study.Breast Cancer Res. 2005;7(4):R513-21. doi: 10.1186/bcr1040. Epub 2005 May 12. Breast Cancer Res. 2005. PMID: 15987458 Free PMC article.
-
Genetic polymorphism of CYP17 and breast cancer risk in Korean women.Exp Mol Med. 2005 Feb 28;37(1):11-7. doi: 10.1038/emm.2005.2. Exp Mol Med. 2005. PMID: 15761247
-
CYP17 5'-UTR MspA1 polymorphism and the risk of premenopausal breast cancer in a German population-based case-control study.Breast Cancer Res. 2005;7(4):R455-64. doi: 10.1186/bcr1027. Epub 2005 Apr 12. Breast Cancer Res. 2005. PMID: 15987450 Free PMC article.
-
Factors influencing the association between CYP17 T34C polymorphism and the risk of breast cancer: meta-regression and subgroup analysis.Breast Cancer Res Treat. 2010 Jul;122(2):471-81. doi: 10.1007/s10549-009-0690-9. Epub 2009 Dec 31. Breast Cancer Res Treat. 2010. PMID: 20043206 Review.
-
CYP17 polymorphisms in relation to risks of prostate cancer and benign prostatic hyperplasia: a population-based study in China.Int J Cancer. 2003 Nov 1;107(2):271-5. doi: 10.1002/ijc.11378. Int J Cancer. 2003. PMID: 12949806 Review.
Cited by
-
Association between CYP17 T-34C rs743572 and breast cancer risk.Oncotarget. 2017 Dec 26;9(3):4200-4213. doi: 10.18632/oncotarget.23688. eCollection 2018 Jan 9. Oncotarget. 2017. PMID: 29423115 Free PMC article.
-
Review of the Gene-Environment Interaction Literature in Cancer: What Do We Know?Genet Epidemiol. 2016 Jul;40(5):356-65. doi: 10.1002/gepi.21967. Epub 2016 Apr 7. Genet Epidemiol. 2016. PMID: 27061572 Free PMC article.
-
CYP17 and breast cancer: no overall effect, but what about interactions?Breast Cancer Res. 2005;7(6):238-42. doi: 10.1186/bcr1320. Epub 2005 Sep 20. Breast Cancer Res. 2005. PMID: 16280038 Free PMC article.
References
-
- Nakajin S, Shinoda M, Haniu M, Shively JE, Hall PF. C21 steroid side chain cleavage enzyme from porcine adrenal microsomes. Purification and characterization of the 17 alpha-hydroxylase/C17,20-lyase cytochrome P-450. J Biol Chem. 1984;259:3971–3976. - PubMed
-
- Picado-Leonard J, Miller WL. Cloning and sequence of the human gene for P450c17 (steroid 17 alpha-hydroxylase/17,20 lyase): similarity with the gene for P450c21. DNA. 1987;6:439–448. - PubMed
-
- Carey AH, Waterworth D, Patel K, White D, Little J, Novelli P, Franks S, Williamson R. Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17. Hum Mol Genet. 1994;3:1873–1876. - PubMed
-
- Nedelcheva Kristensen V, Haraldsen EK, Anderson KB, Lonning PE, Erikstein B, Karesen R, Gabrielsen OS, Borresen-Dale AL. CYP17 and breast cancer risk: the polymorphism in the 5' flanking area of the gene does not influence binding to Sp-1. Cancer Res. 1999;59:2825–2828. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical